摘要
目的比较柔红霉素联合阿糖胞苷（DA方案）与米托蒽醌联合阿糖胞苷（MA方案）诱导治疗初发急性髓系白血病的临床疗效及不良反应。方法将2010年6月至2013年7月68例初诊为急性髓系白血病的患者，随机给予DA方案组（36例）或MA方案组（32例）诱导化疗1个疗程，比较DA方案组与MA方案组的完全缓解率、总有效率及不良反应发生率。结果DA方案组完全缓解（CR）18例（50％），部分缓解（PR）3例（8．3％），总有效率为58．3％（21／36）。MA方案组CR23例（71．2％），PR4例（12．5％），总有效率为84．4％（27／32），两组方案总有效率比较差异有统计学意义（P〈0．05）。MA方案组心脏毒性发生率低于DA方案组，骨髓抑制重于DA方案组。结论MA方案组的疗效优于DA方案组。
Objective To compare the safety and side effects of daunorubicin ＋ cytosine arabinoside（ DA regimen） and mitoxantrone ＋ cytosine arabinoside （ MA regimen） for the first diagnosed acute myeloid leukemia（AML） patients. Methods Sixty-eight patients with acute myeloid leukemia from June 2010 to July 2013 were randomly divided into two groups, including 36 cases with DA regimen and 32 cases with MA regimen. The complete response rate, overall response rate, side effect rate were compared separately. Results In the DA group and the MA group, the rate of complete response, partial re- sponse, and overall response was 50% （18/36） vs. 71.2% （23/32）, 8.3% （3/36） vs. 12.5% （4/32）, 58.3% （21/36） vs. 84. 4% （27/32） respectively. There were significant differences between the two groups in the overall response rates （ P 〈 0. 05 ） . The cardiotoxicity incidence of MA group was lower than that of DA group, while bone marrow suppression was heavier than that of DA group. Conclusions MA regimen is superior to DA regimen.
出处
《中国实用医刊》
2014年第6期67-69,共3页
Chinese Journal of Practical Medicine
关键词
急性髓系白血病
米托蒽醌
柔红霉素
阿糖胞苷
Acute myeloid leukemia
Mitoxantrone
Daunorubicin
Cytosine arabinoside
